Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 7,073 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Recruiting Phase 2 Interventional

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

NCT06897488
View directory record Official record
Conditions
Breast Cancer
Interventions
Adjuvant Radiotherapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

NCT00724386
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Vinorelbine, Filgrastim, Radiation
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 27, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

NCT00006370
View directory record Official record
Conditions
Breast Cancer, Lung Cancer
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 27, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

NCT03765983
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, GDC-0084
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Completed No phase listed Observational

Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging

NCT02510456
View directory record Official record
Conditions
Breast Cancer
Interventions
Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort, Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 27, 2026, 5:09 AM EDT
Terminated Phase 1 Interventional Results available

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

NCT02659631
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06671008
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Harrison, New York • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 27, 2026, 5:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

NCT03742102
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

NCT00203372
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab 7.5 and TAC, Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), Bevacizumab 15 and TAC, Placebo 15 and TAC
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Los Angeles, California • Pomona, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 27, 2026, 5:09 AM EDT
Active, not recruiting Phase 1 Interventional

Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

NCT03988595
View directory record Official record
Conditions
Hormone Receptor Positive Metastatic Breast Cancer
Interventions
Exercise Treatment
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

NCT00079157
View directory record Official record
Conditions
Breast Cancer
Interventions
incomplete Freund's adjuvant, sargramostim, telomerase: 540-548 peptide vaccine
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 27, 2026, 5:09 AM EDT
Recruiting Phase 1 Interventional

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

NCT06908928
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
bulumtatug fuvedotin
Drug
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

NCT04090567
View directory record Official record
Conditions
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Cediranib, Ceralasertib, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Tamoxifen-MRI Study

NCT00295100
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 45 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2007 · Synced Oct 27, 2026, 5:09 AM EDT
Active, not recruiting Not applicable Interventional

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

NCT03865992
View directory record Official record
Conditions
Breast Cancer, Joint Pain
Interventions
Curcumin, Placebo, Nanoemulsion, Quality-of-Life Assessment, Questionnaire
Dietary Supplement · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Duarte, California • Rancho Cucamonga, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study

NCT04474834
View directory record Official record
Conditions
Breast Cancer
Interventions
Polygenic Risk Score
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
737 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Active, not recruiting No phase listed Observational

Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)

NCT01992432
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

NCT03012230
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Ruxolitinib Phosphate
Other · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 27, 2026, 5:09 AM EDT
Active, not recruiting Phase 2 Interventional

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

NCT00877500
View directory record Official record
Conditions
Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
Interventions
Best Practice, Ixabepilone
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
3
States / cities
Oak Lawn, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Withdrawn Phase 2 Interventional

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

NCT00003536
View directory record Official record
Conditions
Stage IV Breast Cancer, Recurrent Breast Cancer
Interventions
antineoplaston A10, methotrexate, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, chemotherapy, complementary and alternative therapy, differentiation therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 27, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study

NCT02682836
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Walk with Ease
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 27, 2026, 5:09 AM EDT
Recruiting Phase 1 Interventional

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

NCT04282044
View directory record Official record
Conditions
Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Interventions
CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
Biological · Combination Product
Lead sponsor
BioEclipse Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 27, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

NCT04305834
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Abemaciclib, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
70 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Long Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

NCT00984399
View directory record Official record
Conditions
Atrophic Vaginitis, Breast Cancer
Interventions
Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 27, 2026, 5:09 AM EDT
Active, not recruiting No phase listed Observational

Elevate! : An Elderly Breast Cancer Cohort Study

NCT03818087
View directory record Official record
Conditions
Breast Cancer
Interventions
Observational cohort
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
70 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
4
States / cities
Bangor, Maine • Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 27, 2026, 5:09 AM EDT